First BTK Inhibitor Approved for Immune Thrombocytopenia

(MedPage Today) — The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday.
As the first Bruton’s tyrosine kinase (BTK) inhibitor for ITP, the indication stipulates…